Actively Recruiting
Combining Biomarkers and Electronic Risk Scores to Predict AKI in Hospitalized Patients
Led by University of Chicago · Updated on 2025-09-12
800
Participants Needed
2
Research Sites
216 weeks
Total Duration
On this page
Sponsors
U
University of Chicago
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study's objective is to evaluate the additive value of renal biomarkers (from blood and urine) for identifying individuals at high risk for severe acute kidney injury (AKI) above that of a novel natural language processing (NLP)-based AKI risk algorithm. The risk algorithm is based on electronic health records (EHR) data (labs, vitals, clinical notes, and test reports). Patients will enroll at the University of Chicago Medical Center and the University of Wisconsin Hospital, where the risk score will run in real time. The risk score will identify those patients with the highest risk for the future development of Stage 2 AKI and collect blood and urine for biomarker measurement over the subsequent 3 days.
CONDITIONS
Official Title
Combining Biomarkers and Electronic Risk Scores to Predict AKI in Hospitalized Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- E-STOP AKI 2.0 score in the top 10% of risk within the last 12 hours during this hospital stay
- Admitted to inpatient ward, intermediate care, or ICU at University of Chicago Medical Center or University of Wisconsin Health
- Patient or legal representative can read, speak, and understand English for consenting purposes
You will not qualify if you...
- Voluntary refusal or missing written consent from patient or legal representative
- Known history of end-stage renal disease on dialysis or kidney transplant
- No serum creatinine measured during inpatient stay
- Serum creatinine greater than 4.0 mg/dl at admission or within last 6 months
- Prior episode of KDIGO defined AKI during this hospitalization
- Prior renal consultation during admission
- E-STOP AKI 2.0 score above top 10% risk threshold more than 12 hours ago during this hospital stay
- Incarcerated patients
- Pregnant patients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
University of Chicago Medical Center
Chicago, Illinois, United States, 60637
Actively Recruiting
2
University of Wisconsin Hospital
Madison, Wisconsin, United States, 53792
Actively Recruiting
Research Team
J
Jay Koyner, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here